EQ-5D and the EuroQol Group: Past, Present and Future

Devlin, Nancy; Brooks, Richard

doi:10.1007/s40258-017-0310-5

Cited by 816 publications

(689 citation statements)

References 34 publications

Supporting

Mentioning

636

Contrasting

Unclassified

Order By: Relevance

“…The Diabetes-39 (D-39) is the most widely used non preference-based condition-specific instrument addressing the HRQoL of diabetic patients [8], while the EQ-5D is the most widely used generic preference-based instrument [9][10][11]. Over 17,000 studies using the EQ-5D instrument have been registered with the EuroQol Group by 2015 [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Do country-specific preference weights matter in the choice of mapping algorithms? The case of mapping the Diabetes-39 onto eight country-specific EQ-5D-5L value sets

et al. 2018

View full text Add to dashboard Cite

Purpose: To develop mapping algorithms that transform Diabetes-39 (D-39) scores onto EQ-5D-5L utility values for each of eight recently published country-specific EQ-5D-5L value sets, and to compare mapping functions across the EQ-5D-5L value sets.Methods: Data include 924 individuals with self-reported diabetes from six countries. The D-39 dimensions, age and gender were used as potential predictors for EQ-5D-5L utilities, which were scored using value sets from eight countries (England, Netherland, Spain, Canada, Uruguay, China, Japan and Korea). Ordinary least squares, generalized linear model, beta binomial regression, fractional regression, MM-estimation, and censored least absolute deviation were used to estimate the mapping algorithms. The optimal algorithm for each country-specific value set was primarily selected based normalized root mean square error (NRMSE), normalized mean absolute error (NMAE) and adjusted-r 2 . Cross-validation with 5-fold approach was conducted to test the generalizability of each model. Results:The fractional regression model with loglog as a link function consistently performed best in all country-specific value sets. For instance, the NRMSE (0.1282) and NMAE (0.0914) were the lowest, while adjusted-r 2 was the highest (52.5%) when the English value set was considered. Among D-39 dimensions, the energy and mobility was the only one that was consistently significant for all models. Conclusions:The D-39 can be mapped onto the EQ-5D-5L utilities with good predictive accuracy. The fractional regression model, which is appropriate for handling bounded outcomes, outperformed other candidate methods in all country-specific value sets. However, the regression coefficients differed reflecting preference heterogeneity across countries.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Over 17,000 studies using the EQ-5D instrument have been registered with the EuroQol Group by 2015 [11]. Further, the United Kingdom (UK) National…”

Section: Introductionmentioning

confidence: 99%

Do country-specific preference weights matter in the choice of mapping algorithms? The case of mapping the Diabetes-39 onto eight country-specific EQ-5D-5L value sets

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The quality of life was assessed through the EQ5D questionnaire (Devlin, 2017). Both section of EQ5D were used – VAS and EQ5D questionnaire.…”

Section: Methodsmentioning

confidence: 99%

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines

et al. 2018

View full text Add to dashboard Cite

Biological medicines are considered as a cornerstone in the therapy of rheumatoid arthritis (RA). They change the course of the disease and improve the quality of life of patients. To this date there has been no study comparing the quality of life of and cost of RA therapy in Bulgaria. This fact is what provoked our interest toward this research. The aim of this study is to analyse the cost and quality of life of patients with RA threated with biological medicines in Bulgaria. This is an observational, real life study of 124 patients treated with biological medicines during 2012–2016 at the University hospital “St. Ivan Riskli” in Sofia, specialized in rheumatology disease therapy. Patients were recruited after their consecutive transfer from non-biological to biological medicines. The yearly pharmacotherapy cost was calculated with tocilizumab (n = 30), cetrolizmab (n = 16), golimumab (n = 22), etanercept (n = 20), adalimumab (n = 20), rituximab (n = 16). Three measurements of the quality of life (QoL) were performed with EQ5D—at the beginning of the therapy, after 6 months and after 1 year of therapy. Both section of EQ5D were used—VAS and EQ5D questionnaire. Cost—effectiveness was calculated for unit of improvement in EQ5D score for a one year period and decision model was built with TreeAgePro software. The observed cost of therapy varied between 12 thousand Euros for tocilizumab to 6 thousand Euros for rituximab. All biological medicines let to substantial increase in the quality of life of the patients. Patients on tocilizumab increased their QoL from 0.43 to 0.63 after 1 year; on cetrolizumab from 0.32 to 0.56; on golimumab from 0.41 to 0.67; on etanercept from 0.45 to 0.62; on adalimumab from 0.43 to 0.57; on rhituximab from 0.46 to 0.66. The cost-effectiveness estimates of different biological therapies also varied between 66 to 30 thousand Euros for unit of improvement in the EQ5D during one the course of the year. Therapy with biological medicines improves statistically significant the quality of life of patients, measured through VAS and EQ5D scales. Despite the improvement in the quality of life all biological medicines appears not to be note cost-effective due to their high incremental cost-effectiveness ration (ICER). Rituximab's incremental ratio has (ICER) falls closer to the three times gross domestic product per capita threshold and should be considered as preferred alternatives for RA therapy. In general we can conclude that the treatment of rheumatoid arthritis with biologicals improves quality of life significantly. Only rituximab was cost-effective.

show abstract

“…This questionnaire included elements from the Danish National Health Survey [7] and the EQ-5D-5L questionnaire [8]. The VISP started in August 2014 and is ongoing.…”

Section: Methodsmentioning

confidence: 99%

Use of point‐of‐care HbA_1c measurement to estimate the level of undiagnosed diabetes mellitus among 67‐year‐old participants in a cardiovascular screening programme in the municipality of Viborg, Denmark

et al. 2018

View full text Add to dashboard Cite

show abstract

EQ-5D and the EuroQol Group: Past, Present and Future

Cited by 816 publications

References 34 publications

Do country-specific preference weights matter in the choice of mapping algorithms? The case of mapping the Diabetes-39 onto eight country-specific EQ-5D-5L value sets

Do country-specific preference weights matter in the choice of mapping algorithms? The case of mapping the Diabetes-39 onto eight country-specific EQ-5D-5L value sets

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines

Use of point‐of‐care HbA_1c measurement to estimate the level of undiagnosed diabetes mellitus among 67‐year‐old participants in a cardiovascular screening programme in the municipality of Viborg, Denmark

Contact Info

Product

Resources

About

EQ-5D and the EuroQol Group: Past, Present and Future

Cited by 816 publications

References 34 publications

Do country-specific preference weights matter in the choice of mapping algorithms? The case of mapping the Diabetes-39 onto eight country-specific EQ-5D-5L value sets

Do country-specific preference weights matter in the choice of mapping algorithms? The case of mapping the Diabetes-39 onto eight country-specific EQ-5D-5L value sets

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines

Use of point‐of‐care HbA1c measurement to estimate the level of undiagnosed diabetes mellitus among 67‐year‐old participants in a cardiovascular screening programme in the municipality of Viborg, Denmark

Contact Info

Product

Resources

About

Use of point‐of‐care HbA_1c measurement to estimate the level of undiagnosed diabetes mellitus among 67‐year‐old participants in a cardiovascular screening programme in the municipality of Viborg, Denmark